Myriad Genetics Wins FDA SPMA Nod for BRACAnalysis CDx

Myriad Genetics Wins FDA SPMA Nod for BRACAnalysis CDx

Source: 
Yahoo/Zacks.com
snippet: 

Myriad Genetics, Inc. MYGN has moved one step forward in acquiring the FDA approval for the company’s BRACAnalysis CDx test to be used as a companion diagnostic with Pfizer’s PFE PARP inhibitor, talazoparib.